2006
A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration
Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA, Group C. A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration. Ophthalmology 2006, 113: 1522.e1-1522.e14. PMID: 16876249, DOI: 10.1016/j.ophtha.2006.05.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overChoroidal NeovascularizationDose-Response Relationship, DrugFemaleFluorescein AngiographyHumansInfusions, IntravenousMacular DegenerationMaleMaximum Tolerated DoseMiddle AgedReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaTomography, Optical CoherenceVisual AcuityConceptsVascular endothelial growth factor trapAge-related macular degenerationVEGF TrapRetinal thicknessVisual acuityMacular degenerationEarly Treatment Diabetic Retinopathy Study protocolNeovascular age-related macular degenerationDiabetic Retinopathy Study protocolPlacebo-controlled clinical trialDoses 2 weeksDose-limiting toxicityPhase I trialMean percent changeVEGF receptor 1Optical coherence tomographyAdverse eventsI trialDose groupChoroidal neovascularizationStudy protocolClinical trialsStudy populationMultiple administrationsTherapeutic window
1993
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.
Woodward WR, Olanow CW, Beckner RM, Hauser RA, Gauger LL, Cedarbaum JM, Nutt JG. The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993, 43: 1704-8. PMID: 8414016, DOI: 10.1212/wnl.43.9.1704.Peer-Reviewed Original ResearchMeSH KeywordsAmino AcidsBiological TransportBlood-Brain BarrierHumansInfusions, IntravenousLevodopaMaleMiddle AgedParkinson DiseasePhenylalanineConceptsL-DOPAMotor responseLarge neutral amino acidsVentricular CSF concentrationsAdvanced Parkinson's diseaseL-DOPA infusionL-DOPA levelsClinical responseParkinsonian patientsCSF concentrationsOral administrationNeutral amino acidsParkinson's diseaseInfusionPatientsPhenylalanine challengeReliable predictorCSFVDiseaseBrainDurationResponsePlasmaLevelsAdministration